Alimera Sciences (ALIM) Downgraded by ValuEngine

ValuEngine downgraded shares of Alimera Sciences (NASDAQ:ALIM) from a sell rating to a strong sell rating in a research note issued to investors on Sunday.

A number of other equities research analysts have also weighed in on the stock. Zacks Investment Research upgraded shares of Alimera Sciences from a sell rating to a hold rating in a report on Friday, September 8th. HC Wainwright restated a buy rating and issued a $5.00 target price on shares of Alimera Sciences in a report on Wednesday, August 30th. Finally, Cowen restated a buy rating on shares of Alimera Sciences in a report on Thursday, November 2nd. Two equities research analysts have rated the stock with a sell rating and three have assigned a buy rating to the company’s stock. Alimera Sciences currently has a consensus rating of Hold and a consensus target price of $3.38.

Shares of Alimera Sciences (NASDAQ:ALIM) opened at $1.29 on Friday. The company has a current ratio of 4.84, a quick ratio of 4.65 and a debt-to-equity ratio of -0.71. Alimera Sciences has a fifty-two week low of $1.06 and a fifty-two week high of $1.72.

A number of hedge funds have recently modified their holdings of ALIM. KCG Holdings Inc. grew its position in Alimera Sciences by 127.0% in the 1st quarter. KCG Holdings Inc. now owns 78,604 shares of the biopharmaceutical company’s stock worth $110,000 after purchasing an additional 43,977 shares in the last quarter. JW Asset Management LLC grew its position in shares of Alimera Sciences by 15.6% during the 2nd quarter. JW Asset Management LLC now owns 966,000 shares of the biopharmaceutical company’s stock valued at $1,343,000 after acquiring an additional 130,000 shares during the period. PNC Financial Services Group Inc. grew its position in shares of Alimera Sciences by 24.3% during the 2nd quarter. PNC Financial Services Group Inc. now owns 180,300 shares of the biopharmaceutical company’s stock valued at $251,000 after acquiring an additional 35,200 shares during the period. Finally, Stonepine Capital Management LLC grew its position in shares of Alimera Sciences by 158.2% during the 3rd quarter. Stonepine Capital Management LLC now owns 477,226 shares of the biopharmaceutical company’s stock valued at $644,000 after acquiring an additional 292,399 shares during the period. 41.85% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Alimera Sciences (ALIM) Downgraded by ValuEngine” was originally published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this piece of content on another publication, it was illegally copied and republished in violation of US and international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.chaffeybreeze.com/2017/12/07/alimera-sciences-alim-downgraded-by-valuengine.html.

Alimera Sciences Company Profile

Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Alimera Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply